BioCryst Pharmaceuticals (BCRX)

Executive Summary

BioCryst Pharmaceuticals is a commercial-stage biotech focused on rare diseases, with a marketed product ORLADEYO (berotralstat) for hereditary angioedema (HAE) prophylaxis. The company's proprietary structure-guided drug design platform supports a pipeline including BCX10013, an oral Factor D inhibitor for complement-mediated diseases like paroxysmal nocturnal hemoglobinuria (PNH) and C3 glomerulopathy (C3G). Recent Phase 1 data for BCX10013 showed encouraging safety and pharmacokinetics, supporting advancement into Phase 2. BioCryst also continues to expand ORLADEYO's label and global reach. Financially, the company generates growing revenue from ORLADEYO, which provides a foundation for pipeline investments. Key upcoming catalysts include Phase 2 data readouts for BCX10013 and potential regulatory submissions for label expansions.

Upcoming Catalysts (preview)

• H2 2026Phase 2 data for BCX10013 in PNH or C3G60% success
• 2026FDA approval for ORLADEYO label expansion or pediatric indication70% success
• 2026Partnership or licensing deal for BCX10013 in other complement indications50% success